Skip to main content

Advertisement

SpringerLink
Log in

Reversible posterior leukoencephalopathy syndrome in cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Reversible posterior leukoencephalopathy syndrome (RPLS) is a subacute neurological syndrome typically manifesting with headache, cortical blindness, and seizures. The syndrome is associated with risk factors such as malignant hypertension, eclampsia, and renal failure. Numerous case reports depict its occurrence in cancer patients. The direct causal relationship for the mechanism of RPLS in cancer patients has not yet been defined. Cytotoxic chemotherapy may cause direct endothelium damage, which would impact the blood-brain barrier. Chemotherapies also cause elevations in blood pressure; this is significant because RPLS onset may be solely related to hypertension. An increased number of case reports involving new targeted agents suggests that RPLS incidence may increase in the future. Agents such as bevacizumab and sorafenib have been implicated in new cases of RPLS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hinchey J, Chaves C, Appignani B, et al.: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996, 334:494–500.

    Article  PubMed  CAS  Google Scholar 

  2. Glusker P, Recht L, Lane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354:980–981.

    Article  PubMed  CAS  Google Scholar 

  3. Magnano M, Bush T, Herrera I, et al.: Reversible posterior leukoencephalopathy in patients with systemic lupus erythematous. Semin Arthritis Rheum 2006, 35:396–402.

    Article  PubMed  Google Scholar 

  4. Govindarajan R, Adusumilli J, Baxter DL, et al.: Reversible posterior leukoencephalopathy syndrome induced by raf kinase inhibitor bay 43-9006. J Clin Oncol 2006, 24:e48.

    Article  PubMed  Google Scholar 

  5. Stott V, Hurrell M, Anderson T, et al.: Reversible posterior leukoencephalopathy syndrome; a misnomer reviewed. Intern Med J 2005, 35:83–90.

    Article  PubMed  CAS  Google Scholar 

  6. Garg RK: Posterior leukoencephalopathy syndrome. Postgrad Med J 2001, 77:24–28.

    Article  PubMed  CAS  Google Scholar 

  7. Covarrubias D, Luetmer P, Campeau N: Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 2002, 23:1038–1048.

    PubMed  Google Scholar 

  8. Allen J, Adlakha A, Bergethon P: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006, 63:1475–1478.

    Article  PubMed  Google Scholar 

  9. Norden A, Batchelor T: Reversible posterior leukoencephalopathy syndrome. Onkologie 2007, 30:90–91.

    Article  PubMed  Google Scholar 

  10. Sander T, Clayman D, Sanchez-Ramos L, et al.: Brain in eclampsia: MR imaging with clinical correlation. Radiology 1991, 180:475–478.

    Google Scholar 

  11. Strandgaard S, Paulson O: Cerebral autoregulation. Stroke 1994, 15:413–417.

    Google Scholar 

  12. Edvinsson L, Oman C, Sjoberg N: Autonomic nerves, mast cells, and amine receptors in human brain vessels. Brain Res 1976, 15:377–393.

    Article  Google Scholar 

  13. Benigni A, Morigi M, Perico N, et al.: The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation 1992, 54:775–780.

    Article  PubMed  CAS  Google Scholar 

  14. Fogo A, Hakim R, Sugiura M, et al.: Severe endothelial injury in a renal transplant patient receiving cyclosporine. Transplantation 1990, 49:1190–1192.

    Article  PubMed  CAS  Google Scholar 

  15. Miyazaki Y, Tajima Y, Sodo K, et al.: Hodgkin’s disease related central nervous system angiopathy presenting as reversible posterior leukoencephalopathy. Intern Med 2004, 43:900–901.

    Article  Google Scholar 

  16. Rangi PS, Partridge W, Newlands ES, Waldman AD: Posterior reversible leukoencephalopathy syndrome: a possible late interaction between cytotoxic agents and general anesthesia. Neuroradiology 2005, 47:586–590.

    Article  PubMed  CAS  Google Scholar 

  17. Ozcan C, Wong SJ, Hari P: Reversible posterior leukoencephalopathy and bevacizumab. N Engl J Med 2006, 354:980–982.

    Article  PubMed  Google Scholar 

  18. Paul F, Aktas O, Dieste FJ, et al.: Reversible posterior leukoencephalopathy after chemotherapy with cisplatin and 5-FU [in German]. Nervenarzt 2006, 77:706–710.

    Article  PubMed  CAS  Google Scholar 

  19. Connolly RM, Doherty CP, Beddy P, O’Byrne K: Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer 2007, 56:459–463.

    Article  PubMed  Google Scholar 

  20. Haefner M, Siciliano R, Widmer L, et al.: Reversible posterior leukoencephalopathy after treatment of diffuse large B cell lymphoma. Onkologie 2007, 30:138–140.

    Article  PubMed  Google Scholar 

  21. Bauwens D, Hanston P, Laterre PF, et al.: Recurrent seizures and sustained encephalopathy associated with dimethylsulfoxide-preserved stem cell infusion. Leuk Lymphoma 2005, 46:1671–1679.

    Article  PubMed  CAS  Google Scholar 

  22. Zhang SZ, Wang ZH, Hu HS: Effect of intra-arterial perfusion of cisplatin combined with concomitant radiation therapy on the healing of microvasculature anastomoses: an experimental study in rabbits [in Chinese]. Shanghai Kou Qiang Yi Xue 2005, 14:490–494.

    PubMed  Google Scholar 

  23. Ito Y, Arahata Y, Goto Y, et al.: Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998, 19:415–417.

    PubMed  CAS  Google Scholar 

  24. Walker RW, Rosenblum MK, Kempin SJ, Christian MC: Carboplatin associated thrombotic microangiopathic hemolytic anemia. Cancer 1989, 64:1017–1020.

    Article  PubMed  CAS  Google Scholar 

  25. Divix L, Libura M, Libura J, et al.: In vitro toxicity studies with mitomycin and bleomycin on endothelium cells. Anticancer Drugs 1997, 9:859–868.

    Google Scholar 

  26. Tam C, Galanos J, Seymour J, et al.: Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for malignancies. Am J Hematol 2004, 77:72–76.

    Article  PubMed  CAS  Google Scholar 

  27. Delanty N, Vaughan C, Frucht S, Stubgen P: Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology 1997, 49:686–689.

    PubMed  CAS  Google Scholar 

  28. Irvin W, MacDonald G, Smith JK, Kim WY: Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol 2007, 11:2484–2485.

    Article  Google Scholar 

  29. Bodkin C, Eidelman H: Sirolimus induced posterior reversible encephalopathy. Neurology 2007, 68:2039–2040.

    Article  PubMed  Google Scholar 

  30. Serkova N, Christian U, Flogel U, et al.: Assessment of the mechanism of astrocyte swelling induced by the macrolide immunosuppressant sirolimus using multinuclear nuclear magnetic resonance spectroscopy. Chem Res Toxicol 1997, 10:1359–1363.

    Article  PubMed  CAS  Google Scholar 

  31. Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 2007, 356:2271–2281.

    Article  PubMed  CAS  Google Scholar 

  32. Levine R, Karumanchi S: Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005, 48:372–386.

    Article  PubMed  Google Scholar 

  33. Motzer R, Bukowski R: Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006, 24:5601–5608.

    Article  PubMed  CAS  Google Scholar 

  34. Ledingham J, Rajagopalan B: Cerebral complications of accelerated hypertension. Q J Med 1979, 48:25–41.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of Virginia Health System, PO Box 800716, Charlottesville, VA, 22908, USA

    Christopher Vaughn

Authors
  1. Christopher Vaughn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louann Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Schiff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher Vaughn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vaughn, C., Zhang, L. & Schiff, D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 10, 86–91 (2008). https://doi.org/10.1007/s11912-008-0013-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-008-0013-z

Keywords

Search

Navigation